Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament for infantile autism caused by hypoxic-ischemic brain injury and preparation method thereof

A technology for hypoxia-ischemia and brain injury, which can be applied to medical formulas, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as insignificant efficacy of brain injury functions

Active Publication Date: 2021-09-14
广东康盾高新技术产业集团股份公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Aiming at the occurrence matrix of hypoxic-ischemic brain injury, the corresponding drugs can alleviate or block the energy failure of brain cells and free radical damage. A composition that maintains glutamate transporter GLT-1 on the astrocyte membrane and reduces extracellular glutamate concentration during injury, but has no significant functional effect on brain injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for infantile autism caused by hypoxic-ischemic brain injury and preparation method thereof
  • Medicament for infantile autism caused by hypoxic-ischemic brain injury and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 20 parts of ganoderma acid derivatives, 18 parts of total triterpenes of ganoderma lucidum, 26 parts of ligustrazine hydrochloride, 22 parts of bilobalide, 10 parts of teretin B, 12 parts of luteolin, 3 parts of pyridoxine.

Embodiment 2

[0023] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 50 parts of ganoderma acid derivatives, 45 parts of total triterpenes of ganoderma lucidum, 30 parts of ligustrazine hydrochloride, 34 parts of bilobalide, 20 parts of teretin B, 22 parts of luteolin, 15 parts of pyridoxine.

Embodiment 3

[0025] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 30 parts of ganoderma acid derivatives, 35 parts of total triterpenoids of ganoderma lucidum, 28 parts of ligustrazine hydrochloride, 28 parts of bilobalide, 15 parts of luteolin, 17 parts of luteolin, and 10 parts of pyridoxine.

[0026] The raw materials in parts by weight of the above-mentioned embodiments 1-3 are prepared by the following preparation method:

[0027] Step (1): dissolving ligustrazine hydrochloride, bilobalide, teretin, and luteolin in ethanol with a mass fraction of 85%, mixing and stirring to prepare a suspension with a drug concentration of 150 mg / mL;

[0028] Step (2): Dissolving ganoderma acid derivatives, ganoderma total triterpenes, and pyridoxine in water, stirring evenly, the stirring rate is 400 rpm, and the stirring time is 100 s;

[0029] Step (3): Mix steps (1) and (2), add 3 times the volume of water...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medicament for infantile autism caused by hypoxic-ischemic brain injury and a preparation method thereof. The medicament comprises the following raw materials in parts by weight: 20-50 parts of ganoderic acid derivatives, 18-45 parts of ganoderma total triterpenes, 26-30 parts of ligustrazine hydrochloride, 22-34 parts of bilobalide, 10-20 parts of aesculetin, 12-22 parts of galuteolin and 3-15 parts of pyridoxine. The medicament provided by the invention has the advantages that the raw materials are reasonably selected and scientifically proportioned, the medicament has an obvious effect on infantile autism caused by hypoxic-ischemic brain injury, and the raw materials are combined to promote glucose and amino acid metabolism in the brain, increase the carotid artery blood flow, improve the cerebral blood flow and protect nerve cells from being damaged by various ischemia and neurotoxins.

Description

technical field [0001] The invention relates to the field of medicine preparation, in particular to a medicament for children with autism caused by hypoxic-ischemic brain injury and a preparation method thereof. Background technique [0002] Children's autism is a subtype of pervasive developmental disorder, with onset before the age of 3, characterized by qualitative impairment of social communication ability, language development disorder, rigid behavior and narrow interests, etc. It is a kind of disease. According to statistics in my country, about 61% of children with autism have mental retardation. It can be seen that most individuals with autism belong to the low-function category; while in high-function autism, the verbal IQ (VIQ ) and operational intelligence quotient (PIQ) test scores are also lower than normal children, which shows that the overall cognitive ability and learning ability of autistic children are poor. The causes of autism are mainly related to geneti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/074A61P9/10A61P25/00A61K31/365A61K31/366A61K31/4415A61K31/4965A61K31/575A61K31/7048
CPCA61K31/575A61K36/074A61K31/4965A61K31/366A61K31/7048A61K31/4415A61K31/365A61P9/10A61P25/00A61K2300/00
Inventor 湛振键刘世豪孟艳芬湛楚沂
Owner 广东康盾高新技术产业集团股份公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com